Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06125366
Other study ID # 19414
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date April 17, 2019
Est. completion date July 11, 2019

Study information

Verified date November 2023
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Japanese healthy male participants: - the safety of BAY1747846 when given at increasing single doses - the level of BAY1747846 in the body over time when given at increasing single doses. To answer the first question, the researchers compared the number and severity of medical problems the Japanese participants had after receiving BAY 1747846 at increasing doses and placebo respectively. Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments. To answer the second question, the researchers determined: - the (average) total level of BAY1747846 in the body, also called AUC - the (average) highest level of BAY1747846 in the body, also called Cmax - how BAY1747846 is removed from the body, also called clearance (CL).


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date July 11, 2019
Est. primary completion date June 19, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria: - Signed informed consent prior to any study specific tests or procedures - Ability and willingness to understand and follow study-related instructions - Subject is healthy as determined by the investigator - Japanese male - Age 20 to 40 years (inclusive) at screening visit - Body mass index (BMI): 18.0 to 28.0 kg/m^2(inclusive) - Body weight: at least 50 kg (inclusive) - Subjects of reproductive potential must agree to use condoms whenever having sexual intercourse with a woman of child-bearing potential. This applies to the time period from signing of the ICF to at least 1 week after treatment. Exclusion Criteria: - Current smoker, or has smoked within 3 months prior to screening Clinical Study Protocol - Any severe disease within the last 4 weeks prior to administration of study drug - History of orthostatic hypotension, fainting spells and blackouts - Any malignant tumor and history thereof - Any clinically relevant finding at the physical examination - Any known disposition for allergic, anaphylactoid, hypersensitivity or idiosyncratic reactions, e.g. any history of clinical signs of hypersensitivity reaction to any contrast agent - Any clinically relevant deviation from reference ranges of the laboratory parameters at screening or alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin exceeding the Upper limit of normal range (ULN) by more than 10%, or creatinine above the ULN, or hemoglobin below 12 g/dL - Clinically relevant ECG findings, e.g.: Heart rate <45 or > 90 beats/min, PR >220 msec, QTcF >450 msec, QRS >120 msec, branch bundle block, any sign of coronary heart disease at screening -. Abnormal vital signs, e.g.: Systolic blood pressure <90 or >140 mmHg, Diastolic blood pressure <45 or >90 mmHg at screening - Subjects who have participated in a clinical study of an investigational drug within 4 months or an approved drug within 3 months prior to administration of study drug

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BAY1747846
Single dose; IV injection.
Matching placebo
Single dose; IV injection.

Locations

Country Name City State
Japan SOUSEIKAI Fukuoka Mirai Hospital Fukuoka

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with treatment-emergent adverse events Up to 7 to 10 days after study drug administration (From the time of signing of the ICF until the last visit of follow-up.)
Primary Severity of treatment-emergent adverse events Up to 7 to 10 days after study drug administration (From the time of signing of the ICF until the last visit of follow-up.)
Secondary Maximum observed drug concentration in measured matrix after single dose administration (Cmax) Pre-dose, on Day 1, Day 2, Day 3 and Day 4.
Secondary Area under the concentration vs. time curve from zero to infinity after single dose (AUC) Pre-dose, on Day 1, Day 2, Day 3 and Day 4.
Secondary Total body clearance of drug (CL) Pre-dose, on Day 1, Day 2, Day 3 and Day 4.
Secondary Total body clearance of drug normalized by body weight (CL/bw) Pre-dose, on Day 1, Day 2, Day 3 and Day 4.
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1